Milestone Pharmaceuticals Inc.
MIST
$1.51
-$0.13-7.67%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 64.27% | 47.03% | 25.42% | 15.22% | -10.63% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 51.27% | 31.40% | 11.60% | -7.00% | -32.20% |
| Operating Income | -47.59% | -31.40% | -11.60% | 7.00% | 31.09% |
| Income Before Tax | -51.88% | -35.65% | -14.71% | 5.74% | 30.44% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -51.88% | -35.65% | -14.71% | 5.74% | 30.44% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -51.88% | -35.65% | -14.71% | 5.74% | 30.44% |
| EBIT | -47.59% | -31.40% | -11.60% | 7.00% | 31.09% |
| EBITDA | -47.69% | -31.48% | -11.62% | 7.01% | 31.16% |
| EPS Basic | -17.62% | -1.49% | 17.47% | 37.15% | 51.28% |
| Normalized Basic EPS | -17.63% | -1.51% | 17.45% | 37.14% | 51.28% |
| EPS Diluted | -17.62% | -1.49% | 17.47% | 37.15% | 51.28% |
| Normalized Diluted EPS | -17.63% | -1.51% | 17.45% | 37.14% | 51.28% |
| Average Basic Shares Outstanding | 34.73% | 30.97% | 31.02% | 47.89% | 44.79% |
| Average Diluted Shares Outstanding | 34.73% | 30.97% | 31.02% | 47.89% | 44.79% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |